哌拉西林钠他唑巴坦钠联合乳酸环丙沙星治疗支气管扩张症伴铜绿假单胞菌感染患者的临床效果  

Clinical Effects of Piperacillin Sodium and Tazobactam Sodium Combined with Ciprofloxacin Lactate in the Treatment of Bronchiectasis with Pseudomonas Aeruginosa Infection

作　　者：刘露 LIU Lu(Respiratory Department,Suizhong County Hospital,Huludao 125299,China)

机构地区：[1]辽宁省绥中县医院呼吸科,辽宁葫芦岛125299

出　　处：《中国药物经济学》2021年第8期66-69,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨哌拉西林钠他唑巴坦钠联合乳酸环丙沙星治疗支气管扩张症伴铜绿假单胞菌感染患者的临床效果。方法选取2018年1月至2020年1月绥中县医院收治的70例支气管扩张症伴铜绿假单胞菌感染患者作为研究对象,随机将其分为常规组与试验组,各35例。常规组给予静脉滴注乳酸环丙沙星氯化钠注射液治疗,试验组在对照组基础上给予注射用哌拉西林钠他唑巴坦钠联合治疗,比较两组的治疗效果。结果试验组治疗有效率高于常规组,差异有统计学意义(P<0.05);治疗后,两组患者血清白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)水平低于治疗前,且试验组血清WBC、CRP、PCT水平低于常规组,差异有统计学意义(P<0.05);治疗后,试验组患者细菌清除率高于常规组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论哌拉西林钠他唑巴坦钠联合乳酸环丙沙星治疗支气管扩张症伴铜绿假单胞菌感染临床效果显著,可有效清除致病菌,改善机体炎症反应,且用药安全。Objective To explore the clinical effects of piperacillin sodium and tazobactam sodium combined with ciprofloxacin lactate and sodium chloride injection in the treatment of bronchiectasis with Pseudomonas aeruginosa infection. Methods A total of 70 patients with bronchiectasis complicated with Pseudomonas aeruginosa infection admitted to Suizhong County Hospital were selected as the research objects from January 2018 to January 2020, and were randomly assigned into a conventional group and an experimental group, with 35 cases in each group. The conventional group was treated with ciprofloxacin lactate, and the experimental group was treated with piperacillin sodium and tazobactam sodium combined with ciprofloxacin lactate. The curative effects of the 2 schemes were compared. Results The total effective rate of the experimental group was higher than that of the conventional group, the difference was statistically significant(P<0.05);after treatment, serum white blood cell count(WBC), C-reactive protein(CRP), and procalcitonin(PCT) levels of the 2 groups of patients were lower than before treatment, and the serum WBC, CRP, and PCT levels of the experimental group were lower than those of the routine group, the difference was statistically significant(P<0.05);after treatment, the bacterial clearance rate of the experimental group was higher than that of the conventional group, the difference was statistically significant(P<0.05);the difference in the incidence of adverse reactions between the 2 groups was not statistically significant(P>0.05). Conclusion Piperacillin sodium and tazobactam sodium combined with ciprofloxacin lactate in the treatment of bronchiectasis with Pseudomonas aeruginosa infection has a significant effect, which can eliminate pathogenic bacteria, improve inflammatory reaction, and is safe.

关 键 词：哌拉西林钠他唑巴坦钠 乳酸环丙沙星 支气管扩张症 铜绿假单胞菌 

分 类 号：R562.2[医药卫生—呼吸系统] R978.1[医药卫生—内科学]